The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2in vitro
Author links open overlay panelLeonCalyaJulian D.DruceaMike G.CattonaDavid A.JansbKylie M.WagstaffbShow morehttps://doi.org/10.1016/j.antiviral.2020.104787Get rights and contentUnder a Creative Commons licenseopen access
Ivermectin is an inhibitor of the COVID-19 causative virus (SARS-CoV-2)in vitro.•
A single treatment able to effect ~5000-fold reduction in virus at 48h in cell culture.•
Ivermectin is FDA-approved for parasitic infections, and therefore has a potential for repurposing.•
Ivermectin is widely available, due to its inclusion on the WHO model list of essential medicines.
Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activityin vitro, is an inhibitor of the causative…
View original post 756 more words